See more : Komputronik S.A. (KOM.WA) Income Statement Analysis – Financial Results
Complete financial analysis of Biodesix, Inc. (BDSX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Biodesix, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Mallee Resources Limited (MYL.AX) Income Statement Analysis – Financial Results
- EQB Inc. (EQGPF) Income Statement Analysis – Financial Results
- CTEEP – Companhia de Transmissão de Energia Elétrica Paulista S.A. (TRPL3.SA) Income Statement Analysis – Financial Results
- Suzhou Hailu Heavy Industry Co.,Ltd (002255.SZ) Income Statement Analysis – Financial Results
- South32 Limited (S32.L) Income Statement Analysis – Financial Results
Biodesix, Inc. (BDSX)
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 49.09M | 38.21M | 54.51M | 45.56M | 24.55M | 20.43M |
| Cost of Revenue | 13.01M | 14.15M | 30.52M | 22.00M | 6.07M | 4.41M |
| Gross Profit | 36.08M | 24.06M | 23.99M | 23.56M | 18.48M | 16.03M |
| Gross Profit Ratio | 73.50% | 62.96% | 44.01% | 51.71% | 75.26% | 78.44% |
| Research & Development | 9.99M | 13.10M | 12.79M | 10.82M | 10.47M | 8.19M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 30.64M | 25.90M |
| Selling & Marketing | 0.00 | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| SG&A | 67.39M | 61.46M | 50.52M | 34.86M | 30.64M | 25.90M |
| Other Expenses | 44.00K | 109.00K | -9.00K | 422.00K | -2.38M | -1.24M |
| Operating Expenses | 77.42M | 74.56M | 63.31M | 45.68M | 41.11M | 34.09M |
| Cost & Expenses | 90.43M | 88.72M | 93.82M | 67.67M | 47.18M | 38.49M |
| Interest Income | 0.00 | 8.07M | 4.51M | 18.00K | 55.00K | 24.00K |
| Interest Expense | 9.54M | 8.07M | 4.51M | 7.60M | 3.01M | 2.92M |
| Depreciation & Amortization | 5.51M | 3.60M | 3.18M | 2.90M | 2.79M | 1.74M |
| EBITDA | -37.10M | -53.78M | -35.47M | -20.84M | -24.93M | -21.51M |
| EBITDA Ratio | -75.59% | -131.89% | -72.15% | -47.58% | -90.25% | -85.81% |
| Operating Income | -41.34M | -50.51M | -39.32M | -22.12M | -22.63M | -23.46M |
| Operating Income Ratio | -84.22% | -132.17% | -72.14% | -48.55% | -92.16% | -114.82% |
| Total Other Income/Expenses | -10.80M | -14.86M | -2.22M | -8.42M | -3.99M | -2.71M |
| Income Before Tax | -52.15M | -65.45M | -43.16M | -31.35M | -30.73M | -26.17M |
| Income Before Tax Ratio | -106.23% | -171.27% | -79.18% | -68.81% | -125.15% | -128.06% |
| Income Tax Expense | 0.00 | 14.94M | 1.32M | 5.12M | 629.00K | 211.00K |
| Net Income | -52.15M | -80.39M | -44.48M | -36.47M | -31.36M | -26.17M |
| Net Income Ratio | -106.23% | -210.37% | -81.61% | -80.06% | -127.71% | -128.06% |
| EPS | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| EPS Diluted | -0.64 | -1.91 | -1.63 | -1.37 | -1.23 | -0.99 |
| Weighted Avg Shares Out | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
| Weighted Avg Shares Out (Dil) | 82.11M | 42.10M | 27.37M | 26.56M | 25.49M | 26.54M |
Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights
Analysts Estimate Biodesix, Inc. (BDSX) to Report a Decline in Earnings: What to Look Out for
Biodesix to Present at Cowen's 42nd Annual Healthcare Conference
Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) CEO Scott Hutton on Q3 2021 Results - Earnings Call Transcript
Biodesix to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
Biodesix, Inc. (BDSX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
Biodesix to Report Third Quarter 2021 Financial Results on November 15, 2021
Source: https://incomestatements.info
Category: Stock Reports